NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy; Jackson LM, Parker RM, Mattison DR, editors. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington (DC): National Academies Press (US); 2020 Jul 1.
The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use.
Show details503A
Total estimates of 503A pharmacies vary based largely on how a compounding pharmacy is defined. In a 2016 report, The Pew Charitable Trusts reported a total of more than 32,000 pharmacies in the United States that compound. This value was derived from the listing of pharmacies that report compounding functions in the National Council for Prescription Drug Programs Provider Database as of 2015. Submission of this information to the database was optional and may not represent the true (and current) number of pharmacies that compound (The Pew Charitable Trusts, 2016). However, this estimate does not provide clarity on the extent of compounding services offered. The American Pharmacists Association estimates there are approximately 7,500 pharmacies in the United States that specialize in compounding (APhA, 2020), a substantially lower estimate than the total 503A pharmacies that perform any compounding.
503B
The value of 503B outsourcing facilities are reflective of those registered with the U.S. Food and Drug Administration as of February 2020. See Table E-1.
TABLE E-1Distribution of 503B Outsourcing Facilities by State
| State | Registered 503B Outsourcing Facilities |
|---|---|
| AK | 0 |
| AL | 2 |
| AR | 4 |
| AZ | 4 |
| CA | 6 |
| CO | 4 |
| CT | 2 |
| DC | 0 |
| DE | 0 |
| FL | 9 |
| GA | 0 |
| HI | 0 |
| IA | 0 |
| ID | 1 |
| IL | 0 |
| IN | 0 |
| KS | 2 |
| KY | 0 |
| LA | 0 |
| MA | 2 |
| MD | 0 |
| ME | 0 |
| MI | 0 |
| MN | 1 |
| MO | 2 |
| MS | 0 |
| MT | 0 |
| NC | 1 |
| ND | 0 |
| NE | 0 |
| NH | 0 |
| NJ | 4 |
| NM | 0 |
| NV | 1 |
| NY | 6 |
| OH | 2 |
| OK | 1 |
| OR | 0 |
| PA | 2 |
| RI | 0 |
| SC | 4 |
| SD | 0 |
| TN | 3 |
| TX | 9 |
| UT | 0 |
| VA | 0 |
| VT | 1 |
| WA | 0 |
| WI | 0 |
| WV | 0 |
| WY | 0 |
SOURCE: FDA, 2020.
REFERENCES
- APhA (American Pharmacists Association). Frequently asked questions about pharmaceutical compounding. 2020. [February 3, 2020]. https://www
.pharmacist .com/frequently-asked-questions-about-pharmaceutical-compounding. - FDA (U.S. Food and Drug Administration). Registered outsourcing facilities. 2020. [January 4, 2020]. https://www
.fda.gov/drugs /human-drug-compounding /registered-outsourcing-facilities. - The Pew Charitable Trusts. National assessment of state oversight of sterile drug compounding. Philadelphia, PA: The Pew Charitable Trusts; 2016.
- 503A and 503B Distribution Supplement - The Clinical Utility of Compounded Bioid...503A and 503B Distribution Supplement - The Clinical Utility of Compounded Bioidentical Hormone Therapy
Your browsing activity is empty.
Activity recording is turned off.
See more...